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Herein, a method for the simultaneous determination of the currently prescribed sartan 
drugs (eprosartan, EPR; olmesartan, OLM; losartan, LOS; candesartan, CAN; 
telmisartan, TEL; irbesartan, IRB; and valsartan, VAL), and the biodegradation product 
valsartan acid (VALA), in water samples (raw and treated wastewater, river and tap 
water) was developed. Solid-phase extraction (SPE) and ultra-performance liquid 
chromatography (UPLC) tandem mass spectrometry (MS/MS) were employed as 
concentration and determination techniques, respectively. Different sorbents and elution 
solvents were tested for sample preparation. Under optimized conditions, samples at 
neutral pH (6 to 8 units) were concentrated using mixed-mode (reversed-phase and 
anionic exchange) cartridges. Thereafter, the sorbent was washed with 5 mL of a 
methanol: water (1:1) solution, dried under a nitrogen stream and compounds were 
eluted with 2 mL of methanol: NH3 (98:2). The accuracy of the method (accounting for 
SPE efficiency and matrix effects during electrospray ionization) was investigated using 
solvent-based calibration standards. Global recoveries, obtained for different water 
matrices (tap, river, treated and raw wastewater), ranged from 82% to 134%, with 
standard deviations between 2 and 18%. LOQs varied from 2 to 50 ng L-1. Analysis of 
un-spiked samples confirmed: (1) the incomplete removal of sartans at sewage treatment 
plants (STPs), (2) the formation of VALA during municipal water treatment, and (3) the 
presence of VALA in the processed tap water samples. Additional findings of the current 
study are the detection of hydroxylated derivatives of the sartan drugs IRB and LOS in 
wastewater, and the E-Z isomerization of EPR in environmental water samples. 
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Sartans are a class of pharmaceuticals employed in the treatment of hypertension 
(Giebułtowicz et al., 2016; Oosterhuis et al., 2013). Currently, seven drugs from this 
family are marketed in Europe. After administration, they are excreted through faeces 
and urine (Bayer et al., 2014; Stankiewicz et al., 2015) entering municipal sewers. The 
octanol-water partition coefficients (log Kow) of sartans point out to medium, or to very 
low polarities; however, the existence of acidic moieties in their structures (carboxylic 
acids and/or a tetrazolic ring) converts them in negatively charged species at the pH of 
environmental water samples (Bayer et al., 2014). This fact increases significantly their 
mobility in the aquatic media. 
Some members of the sartan group are often included in multianalyte methodologies 
applied to the screening of emerging pollutants in the aquatic environment (Cantwell et 
al., 2018; Hermes et al., 2018; Nödler et al., 2016), in methods dealing with the analysis 
of cardiovascular drugs (Giebułtowicz et al., 2016; Stankiewicz et al., 2015), and, less 
often, in more specific studies restricted to this family of pharmaceuticals (Bayer et al., 
2014). From these previous works, it can be concluded that sartans are ubiquitous in raw 
wastewater, with average concentrations usually above 1000 ng L-1 (Bayer et al., 2014; 
Stankiewicz et al., 2015). Their removal percentages at municipal sewage treatment 
plants (STPs) are variable. For example, valsartan (VAL) is an easy to degrade 
compound (with removal percentages above 90%) (Bayer et al., 2014; Oosterhuis et al., 
2013). However, irbesartan (IRB) presents low removal efficiencies (Bayer et al., 2014; 
Oosterhuis et al., 2013). Given that: (1) the available removal data for different sartans 
have not always been obtained under identical conditions (for the same STP) ; (2) 
sartans have been recently reported in sludge from STPs (Castro et al., 2018; Ivanová 
et al., 2018) ; and (3) sartan drugs with a biphenyl tetrazolic sub-structure (5 out of the 7 




al., 2014; 2009; Helbling et al., 2010) the reported removal efficiencies at municipal STPs 
must be considered with caution.  
From municipal wastewaters, these compounds reach surface water reservoirs, 
including fresh and coastal waters (Cantwell et al., 2018; Giebułtowicz et al., 2016; 
Moreno-González et al., 2015; Nödler et al., 2016). Some sartans are stable during 
oxidative water treatments (photolysis, free chlorine and ozone addition), either tested at 
laboratory scale (Blum et al., 2017), or applied in tap water production plants (Huerta-
Fontela et al., 2011). In other cases, such as losartan (LOS), transformation products 
arising from chemical oxidative treatments are deemed to be more toxic than the 
precursor drug (Carpinteiro et al., 2019). In addition to their stability during oxidative 
treatments, olmesartan (OLM) and candesartan (CAN) are not removed during soil 
infiltration of treated wastewaters (Hellauer et al., 2018), which is usually employed to 
recharge groundwater aquifers. Thus, the presence of sartan residues in tap water has 
been predicted and confirmed in samples obtained from different European countries, 
such as Germany and Poland (Giebułtowicz et al., 2016; Stankiewicz et al., 2015). 
 In addition to the prescribed drugs, the transformation product VALA is particularly 
concerning as regards its stability and mobility. Previous studies have proved that it is 
resistant to further biodegradation, ozonation, sand and soil filtration (Nödler et al., 2013; 
Schaffer et al., 2015). VALA shows also a low sorption on granular activated carbon, 
although it is susceptible to biodegradation on the surface of this sorbent (Sperlich et al., 
2017). VALA has been found in bank filtrated samples (Hermes et al., 2018) and in tap 
water (Nödler et al., 2013), produced from bank filtrates, in the range of concentrations 
from 57 to 72 ng L-1. 
Sample preparation procedures employed for the extraction and concentration of these 
species are normally based on solid-phase extraction (SPE), using low selectivity 




a relatively large volume of organic solvent (up to 10 mL of methanol or acetone), 
followed by dryness evaporation and re-constitution of the extract before liquid 
chromatography (LC) tandem mass spectrometry (MS/MS) determination (Giebułtowicz 
et al., 2016; Oosterhuis et al., 2013). Such strategy is coherent with the inclusion of some 
members of the sartan family in screening methods dealing with a large number of 
analytes with different properties. On the other side, a finely tuned method covering the 
simultaneous extraction and concentration of all the currently commercialized sartan 
drugs, and VALA, has not been reported yet. 
Herein, an effective analytical procedure for the determination of 7 sartan drugs, and 
VALA, in water samples with different complexities, from municipal wastewater to surface 
and tap water, is developed. Efforts were focused on combining high extraction yields, 
with the lowest possible effect of the sample matrix in the efficiency of ESI ionization, 
minimum consumption of organic solvents and low manipulation of the primary sample 
extract before analysis. The existence of acidic functionalities in the structure of sartans 
was considered to test the viability of selective extraction-concentration approaches 
based on the use of mixed-mode (reversed-phase and anionic exchange) sorbents. The 
optimized method was applied to investigate the occurrence of these compounds in 
wastewater from a medium size city in the Northwest of Spain, as well as in several rivers 
and tap water samples collected in the same geographic area. In addition, the study 
investigates the existence of sartan transformation products, arising from metabolization 
and/or biodegradation processes, in the extracts obtained from waste and river water. 
To this end, accurate MS and product ion scan data were obtained using an LC 
quadrupole time-of-flight (TOF) mass spectrometer. 





Standards of eprosartan (EPR, as mesylate), OLM, LOS (as potassium salt), telmisartan 
(TEL), IRB and VAL were acquired from Sigma-Aldrich (Milwaukee, WI, USA); VALA and 
the internal surrogates (ISs): valsartan acid-d4 (VALA-d4) and irbesartan-d4 (IRB-d4), 
were supplied by Toronto Research Chemicals (North York, ON, Canada). CAN was 
obtained from Alfa Aesar (by Thermo Fisher Scientifics). Individual solutions of each 
compound (600-1000 mg L−1) were prepared in methanol (MeOH). The ISs were 
supplied as methanolic solutions (100 mg L−1). Chemical structures of these compounds 
and some properties of interest to predict their behaviour during sample preparation are 
provided as supplementary information, Table S1.  
MeOH, HPLC-grade purity, glacial formic acid (FA) (98%), and ammonia (NH3, 25% 
solution in methanol) were supplied by Merck (Darmstadt, Germany). Ultra-pure 
deionized water (18.2 MΩ cm−1) was obtained from a Milli-Q Gradient A-10 system 
(Millipore, Billerica, MA, USA). 
2.2. Samples and sample preparation 
Different water matrices have been considered in this research. Wastewater samples 
were obtained from a municipal STP, serving a population of 100.000 inhabitants, 
equipped with primary and biological (activated sludge) treatment units. A detailed 
description of the units in the STP can be found elsewhere (Carballa et al., 2004). River 
water was obtained from different streams known to be affected, or not, by STPs 
discharges in Galicia (Northwest Spain). Some samples of river water were taken in the 
vicinity of drinking water production plants. Tap water samples were obtained from five 
different villages in the same geographic area (Galicia). The geographic coordinates 
corresponding to the different sampling points are provided as supplementary 
information, Table S2. Samples were collected in glass bottles, transported to the 
laboratory at 4ºC, and submitted to the extraction process within the next 48 hours. 




dates were comprised between the 2nd half of July and the middle October 2018. During 
this period, rivers contain the highest proportion of wastewater.  
The extraction and concentration of sartan drugs was carried out by SPE. Several 
sorbents: reversed-phase OASIS HLB (200 and 60 mg) and mixed-mode (reversed-
phase and anionic exchangers) OASIS WAX (150 mg) and OASIS MAX (60 and 150 
mg), all of them provided by Waters (Milford, MA, USA), were investigated for the 
effective and selective concentration of sartans from water samples. Unless otherwise 
stated, SPE conditions were optimized using filtered samples of treated wastewater (400 
mL aliquots) spiked with target compounds at 5000 ng L-1. Breakthrough studies were 
investigated by passing the spiked water samples through each of the above sorbents 
online connected to an OASIS HLB 60 mg cartridge. After the concentration step, 
cartridges were eluted separately. The minimum volume of solvent required to recover 
compounds from SPE cartridges was determined by collecting consecutive fractions of 
2 mL from each of the evaluated solvents. 
Under optimized conditions, water samples, at neutral pH (6 to 8 units) and spiked with 
the ISs, were concentrated using the mixed-mode (reversed-phase and weak anionic 
exchange) 150 mg WAX cartridges. Thereafter, the sorbent was washed with 5 mL of a 
mixture of MeOH: water (1:1), dried with a stream of nitrogen, and eluted with MeOH: 
NH3 (98:2). The volume of extract was limited to 2 mL. This extract was neutralized by 
addition of 0.06 mL of FA (acidification is required to improve the retention of the 
compounds in the UPLC column), passed through a 0.45 µm syringe filter, and injected 
in the UPLC-ESI-MS/MS system. 
 
2.3. LC-MS/MS determination conditions 
Determination of sartan drugs was performed in a LC-MS/MS system (Xevo TQD) 




furnished with a Z-ESI source. Compounds were separated in a UPLC column, Zorbax 
Eclipse Plus C18 rapid resolution (50 mm x 2.1 mm, 1.8 µm), acquired from Agilent 
Technologies (Wilmington, DE, USA). The column was connected to a C18 2.1 mm i.d. 
Security GuardTM cartridge supplied from Phenomenex (Torrance, CA, USA). Column 
and pre-column were maintained at 40 ⁰C. Mobile phases were ultrapure water (A) and 
methanol (B), both containing 0.1% FA. The composition of the mobile phase was 
programmed as follows: 20% B (0-0.5 min), linear rated to 100% B (6-7 min), 20% B 
(7.1-10 min) (Castro et al., 2018). The injection volume was 0.5 µL and the column flow 
0.4 mL min-1. 
Compounds were ionized operating the ESI source in positive mode. Nitrogen (99.999%) 
was employed as nebulization (50 L h−1) and drying gas (450 °C at 1000 L h−1) in the 
ionization source, which was set at 150 °C. Argon (99.99%) was used as collision gas in 
the MRM detection mode. The nebulizer needle was maintained at 1.5 kV. MS/MS 
transitions were recorded within a window of 60 s around the retention time of each 
compound. The dwell-time per transition was automatically adjusted by the MassLynx 
software (also used to control every UPLC-MS/MS parameter) to obtain 12 points per 
peak, considering an average baseline peak width of 5 s. 
A QTOF-MS instrument (Agilent 6550), connected to an Agilent 1260 UPLC system, was 
employed to investigate the identity of an extra peak noticed in the chromatograms 
corresponding to MRM transitions of EPR, and to evaluate the presence of potential 
transformation products of sartan drugs in wastewater. Chromatographic conditions 
were the same as those employed in the QqQ instrument. Accurate MS and product ion 
scan spectra (MS/MS) were acquired operating the ESI source in positive (+) and 
negative (-) ionization modes (in two different injections), whilst the QTOF MS instrument 




Accurate product ion spectra were acquired at four different collision energies: 10, 20, 
30 and 40 eV. 
 
2.4. SPE recoveries, matrix effects and overall extraction efficiencies 
The recoveries of the optimized SPE process, see section 2.2, were assessed for spiked 
(addition level 2000 ng L-1) aliquots of wastewater (400 mL and 200 mL for raw and 
treated water, respectively). Recoveries were calculated as the ratio between responses 
obtained for samples spiked before (addition to water) and after the extraction step 
(addition to the SPE extract). The obtained values were multiplied by 100.  
Potential matrix effects (MEs,%) during ESI(+) ionization were defined as the ratios 
between the slopes of calibration curves prepared with spiked extracts from wastewater 
samples and with solvent-based standards. The obtained values were multiplied by 100. 
Slope ratios below and above 100% point out to a reduction and to an enhancement in 
the efficiency of ESI(+) ionization for sample extracts versus solvent standards, 
respectively. Ratios around 100% suggest similar ionization efficiencies in both cases, 
which is normally associated with a low level of co-extracted organic species in the SPE 
extract. 
Potential compound losses during the filtration step were estimated with the ratios 
between responses obtained for each compound in the extracts from 400 mL aliquots of 
the same treated wastewater sample fortified, at 5000 ng L-1, before and after filtration, 
multiplied by 100. 
Overall extraction efficiencies (accounting for the yield of the SPE step and MEs) were 
calculated as the difference in concentrations measured for spiked and non-spiked 
aliquots of different water matrices divided by the added value. Concentrations existing 




2.5. Eprosartan photoisomerization experiments 
The potential conversion of E-EPR in the Z isomer was investigated with ultrapure water 
solutions, spiked with the former compound (added concentration 500 µg L-1) and 
exposed to sunlight in a quartz tube. Control (zero time) and sample aliquots after 4 h of 
irradiation were injected in the LC-QTOF-MS system. The accurate MS and product ion 
scan spectra of the observed transformation product were compared to those 
corresponding to the EPR analogue detected in river water extracts. 
3. Results and discussion 
3.1. UPLC-ESI-MS/MS parameters 
Table 1 summarizes the most relevant features of the UPLC-MS/MS determination 
procedure, without considering the sample preparation step. Linearity was investigated 
in the range of concentrations from 2.5 to 500 µg L-1 (from 5 to 1000 µg L-1 for VAL), 
considering an injection volume of 0.5 µL. Within this interval, the plots of corrected 
responses (peak area divided by the peak area of the corresponding IS) versus 
concentration fitted a linear model, with determination coefficients (R2) above 0.999. The 
instrumental limits of quantification (LOQs) were estimated from responses obtained for 
the lowest level calibration standard, assuming a signal to noise (S/N) ratio of 10 for the 
quantification transition (Q1), and a ratio between qualification (Q2) and Q1 transitions 
within a 30% of the average value provided in Table 1. LOQs varied from 0.5 µg L-1 for 
IRB up to 5 µg L-1 for VAL.  
3.2. Optimization of SPE conditions 
 SPE conditions were optimized regarding the extraction sorbent, the washing and the 
elution solvents. Three different sorbents: OASIS HLB (200 mg), OASIS MAX (60 and 
150 mg) and OASIS WAX (150 mg), were tested for the retention of sartan compounds 




this sample (7.2 units), the reversed-phase HLB cartridges (200 mg sorbent) failed to 
retain VALA. Around 30% of the response obtained for this compound was noticed in the 
extract from the back on-line connected cartridge (60 mg OASIS HLB). Acidification of 
the water sample (pH 3) overcame breakthrough problems; however, this option is 
recognized to increase the retention of acidic natural organic matter, such as humic and 
fulvic acids, in reversed-phase materials (Fang et al., 2017). Breakthrough problems 
were not noticed for any of the two mixed-mode (OASIS MAX and OASIS WAX, 150 mg) 
cartridges for the same water matrix. 
MeOH and MeOH containing different percentages of FA or NH3 (up to 2%) were tested 
as elution solvents in combination with reversed and mixed-mode sorbents. MeOH 
(2 mL) was effective to recover all compounds from the HLB cartridge; however, it failed 
during elution of mixed-mode sorbents (none of the eight target compounds was 
detected in the first 10 mL obtained from mixed-mode cartridges). As regards the MAX 
sorbent (reversed-phase and strong anionic exchanger), VALA (the most acidic of the 
compounds) showed a slow elution profile using MeOH: FA (98:2) as eluent. More than 
10 mL of solvent were required to recover this compound. Even using the 60 mg 
cartridges, VALA displayed a slow elution profile. Elution of target compounds from the 
WAX cartridges (reversed-phase and weak anionic exchangers) was achieved in the first 
fraction (2 mL) of MeOH:NH3 (98:2). Thus, this polymer was selected to follow with the 
optimization of the extraction process. 
Ultrapure water and MeOH (up to 5 mL) were tested as washing solvents, before elution 
of WAX cartridges. Neither sartans, nor VALA were detected in the corresponding 
washing fractions. On the other hand, the use of acidified water, or MeOH with 1% of 
FA, led to partial desorption of the less acidic sartans (particularly TEL, EPR and IRB). 




values. Thus, their electrostatic interactions with the positively charged sites in the WAX 
sorbent are broken in presence of FA.  
Under optimized conditions, SPE recoveries ranged from 93 to 107%, with standard 
deviations between 1 and 3%, Table 2. MEs (%) were also investigated with both 
matrices, following the procedure described in section 2.4. The ratios between slopes of 
spiked wastewater extracts and solvent-based standards ranged from a minimum of 76% 
to a maximum of 119% (Table 2), pointing out to moderate variations in the efficiency of 
the ESI ionization for sample extracts versus solvent-based standards. 
Filtration losses varied from 82% for TEL (the most lipophilic species) to 93% for VAL, 
Table S3. Thus, compounds remained associated to the water phase, which is in 
agreement with their existence as negatively charged species at pH 7, Table S1.  
 
3.3. Performance of the analytical method 
Taking into account recoveries and MEs compiled in Table 2, the accuracy of the 
developed procedure was evaluated using solvent-based calibration standards. Sample 
aliquots (from 200 to 500 mL depending on the matrix) were spiked with the ISs, fortified 
with target compounds, filtered and concentrated as described above. Non-spiked 
fractions of each matrix (fortified only with ISs) were also processed. Overall extraction 
recoveries (accounting for filtration losses, efficiency of SPE and MEs) were calculated 
as defined in section 2.4. Table 3 summarizes data obtained for different water matrices 
and addition levels. River water was spiked at three different concentration levels 
(attempting to mimic from heavy polluted to pristine surface water samples), and tap 
water at 100 ng L-1, the maximum allowable concentration of most organic pollutants 
(pesticides) in this matrix (Council Directive 98/83/EC, 1998). In both cases, the 
concentrated sample volume was 500 mL. The procedural LOQs of the method for both 




associated standard deviations in the range from 3 to 18%. The LOQs obtained for both 
water types varied from 2 to 20 ng L-1. The pre-concentration factor provided by the 
developed procedure was of 250 times, without the need of a solvent exchange step, 
and/or concentration of the primary SPE extract before injection in the UPLC-ESI-MS/MS 
system. 
In case of raw and treated wastewater, the obtained recoveries and the LOQs, only 
referred to the first and the most complex matrix, are also compiled in Table 3. For these 
matrices, recoveries ranged from 82 to 115%, with standard deviations lower than 16%. 
The linear response range of the method for raw wastewater extended up to 5000 ng L-
1 (10000 ng L-1 for VAL) and the achieved LOQs varied from 5 to 50 ng L -1. For treated 
wastewater, LOQs and the upper limit of the linear response range are twice lower. As 
further comment, all the processed wastewater samples contained relevant 
concentrations of target compounds; so, for this matrix it is practically impossible to verify 
the goodness of LOQs. LOQs reflected in Table 3 for raw wastewater are estimated 
values, considering the enrichment factor provided by the SPE step (100 and 200 times 
for raw and treated wastewater, respectively) and the instrumental LOQs of the UPLC-
ESI-MS/MS system. 
The existence of potential contamination problems was evaluated by processing aliquots 
of ultrapure water (500 mL), spiked with the mixture of ISs, and submitted to the 
developed sample preparation process. None of the target compounds was detected in 
the obtained extracts.  
3.4. Concentrations of sartans in water samples 
The presence of target analytes was assessed in grab samples obtained from four 
different environments: municipal wastewater, rivers affected, or not, by known 
discharges of municipal STPs, rivers used as sources of tap water and tap water 




with calibration standards, and Q2/Q1 ratios within a ± 30% interval of values compiled 
in Table 1. A procedural blank was processed every 5 samples to detect possible 
contamination problems. Table 4 summarizes the obtained data with their standard 
deviations (n=3 replicates). Dates and coordinates of sampling points are provided as 
supplementary information, Table S2. 
Codes 1 to 6 correspond to three pairs of wastewater samples. Each pair was 
simultaneously obtained from the outlet (treated water) and inlet (raw water) flows of the 
same STP. The seven sartans and the degradation product VALA were found in these 
six samples at relevant levels. The highest average concentrations in the raw wastewater 
samples corresponded to VAL and EPR, respectively, Fig. 1A. In some samples, the 
concentrated water volume was reduced to 100 mL in order to maintain compounds 
within the linear response range of the method. From data available from the Spanish 
Drug Agency (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) 
(AEMPS and Service, n.d.), VAL is the most often prescribed drug with 13.7 daily doses 
per 1,000 inhabitants (DHD), and an average of 80 mg of active compound per dose and 
day. In contrast, the lowest prescription rate corresponded to EPR (DHD 0.85); however, 
the daily dose of this drug (average value 600 mg) is the highest within the group of 
sartans; so, it is in the 3rd place as regards the total consumed amount, Table S4. 
Attending to the total consumed amounts, average concentrations of IRB and LOS in the 
processed raw wastewater are lower than expected. 
Fig. 1B displays the average apparent removal efficiencies for the seven sartan drugs in 
the considered STP. Obtained values varied from 80% for EPR to 35% for TEL. Globally, 
these percentages agree with those reported by Bayer and co-workers (Bayer et al., 
2014) for 5 out of the 7 sartan prescription drugs considered in their work. Formation of 




were always higher in the effluent than in the influent samples obtained from the same 
STP, Table 4.  
Codes 7 to 11 correspond to samples obtained from 3 different rivers affected by treated 
wastewater discharges. They were taken 2-4 km downstream the discharge point. In 
case of samples 7 and 8, a fraction of the municipal wastewater flows directly to the river, 
without entering the STP, which explains the relatively high levels of VAL, Table 4. VAL 
was also found at high concentrations in river sample code 9. On the other hand, sample 
codes 10 and 11 (obtained from a small stream affected by discharges from a modern 
STP furnished with primary, biological and UV treatments) contained higher levels of the 
biodegradation species VALA than residues of any of the prescribed sartans. For these 
two samples, the ratio VAL/VALA stayed well below 1, as it is expected for wastewaters 
after the activated sludge treatment (Nödler et al., 2016).  
Sample codes 12 and 13 were obtained in river areas not affected by controlled 
discharges of municipal STPs. Despite this assumption, low concentrations (below 
100 ng L-1) were measured for some of the investigated species, Table 4. Codes 14 to 
21 correspond to pairs of grab samples obtained the catchment areas of drinking water 
production plants, and in the tap water received by consumers. In the four catchments 
points (codes 14, 16, 18 and 20), river water contained low, but measurable, 
concentrations of several sartans and VALA. In the corresponding tap water samples 
(codes 15, 17, 19 and 21) VALA was again ubiquitous, with concentrations in the range 
from 21 to 64 ng L-1. Code 22 corresponds to tap water from a different small village. 
Measured concentrations remain in the same range of values as those found in the 
previous processed samples of tap water (codes 15, 17, 19 and 21). The UPLC 
chromatograms for Q1 and Q2 transitions of VALA for a non-spiked tap water sample 
(code 15, Table 4), and for a procedural blank are shown in the supplementary 





3.5. Isomerization of eprosartan in the aquatic environment 
Fig. 2 shows the UPLC traces for the Q1 and Q2 transitions of EPR in the extracts from 
two different water types: raw wastewater (Fig. 2A) and river water (Fig. 2B). The peak 
observed for the first matrix shows the same retention time as that obtained for the 
commercial standard of the E isomer of EPR. The UPLC traces for river water (code 8, 
Table 4) (Fig. 2B) present a second peak with a slightly longer retention time (0.11 min) 
than that of E-EPR, and a similar Q2/Q1 ratio. The same peak was noticed in all the river 
water samples polluted with E-EPR (codes 7, 8, 9 and 14, Table 4). The accurate ESI(+)-
MS spectra for both peaks (obtained using a UPLC-ESI-QTOF-MS system) confirmed 
that they correspond to species with the same empirical formulae of EPR (C23H24N2O4S). 
In addition, their product ion (MS/MS) spectra contain several common product ions (in 
some cases they present different relative intensities when recorded with the same 
collision energy), Fig. 2C and 2D. Other product ions (i.e. those at m/z values of 163.1226 
and 207.1122) are specific, or display a much higher intensity, for E-EPR, Fig 2C. On 
the contrary, ions at m/z 295.1457, 273.1052 and 162.0368 are more intense in the 
spectrum of the species displaying the longer retention time, Fig. 2D. Differences 
between both spectra are compatible with intramolecular re-arrangement in the 
structures of fragment ions obtained for geometric (E/Z) isomers of EPR. The possibility 
to discriminate between E and Z forms for EPR from their ESI(+) MS/MS spectra has 
been previously recognized in the literature (Brum and Hannah, 1997). The main product 
ions in the low resolution APCI(+)-MS/MS spectra obtained in their previous publication 
matched those shown in Fig. 2C and Fig. 2D. 
To the best of our knowledge, E/Z isomerization of EPR in environmental water samples 
has not been previously reported; however, it is a common process for other emerging 




Photodegradation experiments described in section 2.5 revealed that above 90% of E-
EPR was transformed into a second species, with the same empirical formula, after 4 h 
of solar irradiation. The new compound shows the same retention time as that appearing 
in river water samples polluted with E-EPR. Moreover, the ESI(-) product ion scan 
spectra of both compounds (parent and transformation product) in model 
photodegradation experiments, performed at higher concentrations than those existing 
in environmental samples, are identical, Fig. S2.  
 
3.6. Transformation products of sartan drugs in wastewater 
Chando and co-workers (Chando et al., 1998) have described several metabolites of IRB 
in human faeces and urine after oral administration of the parent drug. Hydroxylation and 
oxidation of non-aromatic carbons in the structure of the compound, together to formation 
of a carboxylic acid derivative were recognized as the main metabolization paths of this 
drug. Considering the possible formation of similar transformation products for other 
sartans, extracts from wastewater samples (codes 1 to 6, Table 4) were injected in the 
UPLC-QTOF-MS system. Thereafter, the pseudo-molecular ions ([M+H]+ and [M-H]-, 
depending on the ionization mode) for the empirical formulae of above described 
transformation products were searched within a mass window of 10 ppm. 
Chromatographic peaks with a significant intensity were noticed only for hydroxylated 
forms of IRB, under positive ionization, and LOS in ESI (+/-). As expected, they showed 
a lower retention in the C18 UPLC column than the parent drugs, Fig. S3. The number of 
double bound equivalents, mass errors (ppm) and normalized score (accounting for 
mass accuracy, isotopic profile and space between ions) obtained from the accurate MS 
spectra of these compounds are given in Table S5. MS data are coherent with 
hydroxylation of precursor drugs, without modifying the number of rings and double 




forms are shown in Fig. S4. The most intense product ion in the spectra of IRB and IRB-
OH appeared 207.0924 Da (calculated mass); thus, the biphenyl tetrazolic substructure 
of the drug is not involved in the hydroxylation reaction. Moreover, the spectrum of IRB-
OH depicted in Fig. S4 matched that previously published for a derivative observed 
during reaction of IRB with free chlorine and assigned to IRB hydroxylated in the terminal 
carbon of the alkyl chain attached to the imidazole ring (Carpinteiro et al., 2019). The 
presence of a hydroxylated form of IRB in treated wastewater and surface water samples 
was also described by Letzel and co-workers (Letzel et al., 2015). However, these 
authors suggested that this species was formed due to biodegradation of IRB in STPs. 
The ESI (+)-MS/MS spectra for both hydroxylated forms of LOS share several common 
ions with those observed in the spectrum of LOS, Fig. S4. These ions confirm again that 
the biphenyl moiety is not involved in the hydroxylation process. Their ESI(-)-MS/MS 
spectra are shown in Fig. 3. The product ions at m/z 187.0640 and 157.0531 Da 
observed in the spectrum of LOS (Fig. 3A) are shifted 15.9949 Da in that of LOS-OH1, 
Fig. 3B. Taking into account the structures assigned to both ions, the hydroxyl group is 
bounded to the butyl group of LOS, likely to the terminal carbon. Above ions are not 
observed for LOS-OH2, whose spectra (Fig. 3C) contained a relevant number of 
fragments. Taking into account the structures assigned to these fragments, formation of 
LOS-OH2 is believed to be the result of hydroxylation of carbon number 5 in the 
imidazole ring, followed by ring opening and oxidation of the hydroxyl group to a carbonyl 
moiety. 
 
The average ratio between the responses of IRB-OH and IRB in raw wastewater was 
0.71 ± 0.05 (n=9 samples). That for the sum of LOS-OH1 and LOS-OH2 divided by the 
response of the parent drug was 0.52 ± 0.05 (n=9 samples). Assuming that both, 




preparation and determination steps, then, the hydroxylated forms of IRB and LOS reach 
significant concentrations in raw wastewater.  
The comparison of the corrected responses for hydroxylated species (compound peak 
area/VALA-d4 peak area) between treated and raw wastewater, normalized to the same 
volume of sample passed through the SPE cartridge, provides a draft estimation of their 
mass balance in the STP. Values above 1 point out to significant hydroxylation of parent 
drugs during the treatment of sewage water. On the other side, ratios below the unit 
mean neat removal of hydroxylated metabolites. The obtained values (0.57 ± 0.14 and 
0.39 ± 0.10 for IRB-OH and the sum of LOS-OH species, respectively) supported the 2nd 
hypothesis.  These data do not serve to discriminate whether these hydroxylated species 
are human excretion metabolites, or biodegradation species generated in sewage; 
however, in the latter case, their formation would take place in an earlier stage, at sewers, 
given that their highest responses were found in the untreated wastewater. 
4. Conclusions 
For the first time, the efficiency of a mixed-mode SPE protocol for the selective extraction 
of the seven currently prescribed sartan drugs, and the biodegradation product VALA, in 
environmental water samples has been demonstrated. In combination with UPLC-ESI-
MS/MS determination, compounds are accurately quantified using solvent-based 
calibration standards, with a low consumption of organic solvents and without a solvent 
exchange step. Data obtained for municipal sewage water confirm the incomplete 
removal of this family of drugs in STPs, as well as the formation of VALA during the 
wastewater treatment process. The existence of hydroxylated forms of IRB and LOS in 
raw wastewater, and the E-Z isomerization of EPR in the aquatic environment are also 
reported for the first time in this study. The systematic occurrence of VALA in tap water 
samples confirms the usefulness of this compound to detect contamination of drinking 




treatments aiming to remove non-biodegradable, polar compounds from water samples 
intended for human consumption. 
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Table 1. Summary of chromatographic and MS/MS determination parameters, linearity (determination coefficient, R2) and limits of quantification 
(LOQs) of the UPLC-MS/MS system, without considering the sample preparation step. 








(2.5–500 µg L-1) 
LOQ 
(µg L-1) 
aEPR 3.43 425.1 55 135.1 (36) 97.1 (30) 0.33 0.9995 2 
aOLM 3.49 447.2 32 207.0 (23) 429.2 (12) 0.69 0.9998 2 
aVALA 3.68 267.1 32 206.1 (18) 178.1 (28) 0.38 0.9998 2.5 
bLOS 4.59 423.0 30 207.0 (20) 405.0 (10) 0.66 0.9997 2 
bCAN 4.63 441.1 30 192.1 (28) 235.1 (22) 0.58 0.9995 3 
bTEL 4.71 515.1 68 276.0 (46) 497.0 (35) 0.57 0.9997 1 
bIRB 4.76 429.0 40 207.0 (26) 195.0 (20) 0.23 0.9998 0.5 
bVAL 5.11 436.0 22 235.0 (18) 207.0 (25) 0.77 0.9997 5 
aVALA-d4 3.66 271.0 32 210.0 (20) 182.0 (30) 0.37 - - 
bIRB-d4 4.75 433.0 40 211.0 (26) 195.0 (20) 0.28 - - 
a, b,  denote the IS assigned to each compound . 





Table 2. Recoveries of the SPE procedure and matrix effects (MEs, %) for wastewater 
samples with their standard deviations (SD). Sample volume 400 and 200 mL for 
treated and raw wastewater. Addition level 2000 ng L-1, n=3 replicates. 
 
 Treated wastewater Raw wastewater 
Compound Recoveries (%) ± SD ME (%) ± SD Recoveries (%) ± SD ME (%) ± SD 
EPR 98 ± 1 99 ± 3 104 ± 2 83 ± 3 
OLM 102 ± 2  113 ± 3 105 ± 2 99 ± 6 
VALA 101 ± 2 101 ± 3 102 ± 3 80 ± 1 
LOS 107 ± 2 104 ± 4 103 ± 2 97 ± 2 
CAN 105 ± 2 105 ± 2 100 ± 2 94 ± 2 
TEL 99 ± 2 104 ± 3 103 ± 1 102 ± 3 
IRB 102 ± 3 99 ± 2 104 ± 2 76 ± 4 






Table 3. Overall recoveries (%) of the analytical procedure for spiked samples of different water types. Mean values, with standard deviations 1 
within parenthesis, obtained against solvent-based standards, n=3 replicates.  2 
 River Water Tap water Treated wastewater Raw wastewater LOQs (ng L-1) 










EPR 104 (14) 102 (6) 93 (7) 101 (8) 84 (12) 109 (5) 91 (11) 99 (9) 8 20 
OLM 134 (6) 111 (7) 96 (9) 125 (14) 96 (10) 104 (4) 108 (3) 109 (7) 8 20 
VALA 108 (12) 114 (10) 93 (6) 101 (4) 97 (16) 99 (7) 103 (2) 100 (12) 10 25 
LOS 111 (18) 100 (7) 112 (4) 96 (11) 96 (11) 106 (4) 110 (5) 102 (7) 8 20 
CAN 115 (14) 102 (8) 92 (6) 90 (11) 91 (6) 103 (8) 107 (2) 91 (9) 12 30 
TEL 98 (8) 102 (13) 112 (5) 91 (6) 98 (9) 103 (5) 107 (5) 105 (13) 4 10 
IRB 105 (12) 98 (8) 111 (4) 88 (4) 82 (9) 93 (7) 93 (2) 95 (11) 2 5 
VAL 132 (9) 104 (9) 106 (5) 99 (3) 88 (7) 115 (4) 115 (7) 107 (9) 20 50 





  8 
29 
 
Table 4. Summary of concentrations (mean values ± SD, ng L-1) measured in different water samples, n=3 replicates. 9 
T.W., treated wastewater; R.W., raw wastewater. 10 
Code Water type (River, village) EPR OLM VALA LOS CAN TEL IRB VAL 
1 T.W. 230 ± 8 972 ± 13 224 ± 9 260 ± 12 219 ± 8 590 ± 27 768 ± 49 1616 ± 60 
2 R.W. 4405 ± 100 1308 ± 44 42 ± 5 605 ± 30 362 ± 40 1037 ± 16 1096± 49 3781 ± 96 
3 T.W. 2284 ± 25 1368 ± 2 1884 ± 36 367 ± 3 257 ± 5 957 ± 3 813 ± 10 1682 ± 16 
4 R.W. 6001 ± 56 2109 ± 43 118 ± 4 627 ± 7 407 ± 17 1340 ± 36 1414 ± 15 9986 ± 87 
5 T.W. 554 ± 10 985 ± 52 1344 ± 17 311 ± 12 289 ± 22 903 ± 20 950 ± 33 927 ± 2 
6 R.W. 5458 ± 124 1932 ± 216 86 ± 36 853 ± 6 497 ± 34 1324 ± 102 1833 ± 38 7242 ± 149 
7 River (Sar) 65 ± 2 429 ± 23 67 ± 4 197 ±  4 136 ± 12 455 ± 13 543 ± 11 1208 ± 45 
8 River (Sar) 2128 ± 26 1294 ± 9 915 ± 9 377 ± 11 258 ± 13 788 ± 2 738 ± 8 3432 ± 2 
9 River (Anllóns) 326 ± 17 264 ± 19 124 ± 16 190 ± 10 61 ± 5 196 ± 19 158 ± 12 956 ± 48 
10 River (Tinto) n.d. 296 ± 7 1439 ± 14 13 ± 2 97 ± 8 219 ± 16 334 ± 7 49 ± 3 
11 River (Tinto) n.d. 702 ± 16 3111 ± 13 19 ± 2 180 ± 20 433 ± 16 543 ± 7 111 ± 3 
12 River (Barbadás) n.d. 26 ± 2 22 ± 2 n.d. n.d. 8 ± 1 30 ± 1 n.d. 
13 River  (Tinto) n.d. n.d. n.d. n.d. n.d. n.d. 12 ± 1 n.d. 
14 River (Arnoia) 59 ± 5 48 ± 4 55 ± 0 n.d. 13 ± 1 20 ± 1 27 ± 0 66 ± 2 
15 Tap (Cartelle) n.d. n.d. 64 ± 4 n.d. 7 ± 2 13 ± 3 n.d. 41 ± 3 
16 River (Tambre) n.d. n.d. 29 ± 4 n.d. n.d. 4 ± 2 13 ± 1 12 ± 3 
17 Tap (Santiago) n.d. n.d. 24 ± 7 n.d. n.d. n.d. n.d. n.d. 
18 River (Ulla) n.d. n.d. 33 ± 5 n.d. n.d. n.d. 15 ± 1 n.d. 
19 Tap (Teo) n.d. n.d. 29 ± 2 n.d. n.d. n.d. n.d. n.d. 
20 River  (Anllóns) n.d. 48 ± 4 108 ± 7 29 ± 1 n.d. 23 ± 1 22 ± 2 107 ± 9 
21 Tap (Carballo) n.d. 8 ± 1 21 ± 7 n.d. n.d. n.d. n.d. 26 ± 8 





Figure 1. Average concentrations of sartan drugs in raw wastewater from a municipal 
STP (A), and apparent removal rates in the same plant (B). Data obtained from 3 pairs 












































Figure 2. MRM chromatograms corresponding to Q1 and Q2 transitions of EPR in non-spiked samples of raw wastewater (A) and river water (B). 
ESI(+) product ion scan spectra obtained for E-EPR (C) and the possible Z isomer (D).  
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Table S1. Chemical structures, CAS numbers and relevant properties of studied compounds. 







133040-01-4 3.75 3.47 (acidic), 6.67(basic) -1.68 -0.18 
Olmesartan OLM 
 




164265-78-5 3.17 4.03, 5.86 (both acidic) -1.90 -1.79 
Losartan LOS 
 
114798-26-4 4.06 4.26 (acidic), 3.82 (basic) -1.00 3.88 
Candesartan CAN 
 
139481-59-7 4.68 3.44 (acidic), 1.5 (basic) -1.93 0.44 
Telmisartan TEL 
 






138402-11-6 5.39 5.85 (acidic), 4.12 (basic) -1.00 4.20 
Valsartan VAL 
 
137862-53-4 4.59 4.00 (acidic), -0.52 (basic) -2.00 0.97 







Table S2. Data corresponding to type of water samples, sampling point and dates. 
 
Code Water type City or River 
Sampling 
date Sampling place coordinates 
1 T.W. STP Santiago 23/07/18 42.870313, -8.598076 
2 R.W. STP Santiago 23/07/18 42.870313, -8.598076 
3 T.W. STP Santiago 06/09/18 42.870313, -8.598076 
4 R.W. STP Santiago 06/09/18 42.870313, -8.598076 
5 T.W. STP Santiago 26/09/18 42.870313, -8.598076 
6 R.W. STP Santiago 26/09/18 42.870313, -8.598076 
7 River Sar 23/07/18 42.857623, -8.631209 
8 River Sar 06/09/18 42.857623, -8.631209 
9 River Anllóns 31/09/18 43.202444,- 8.713944 
10 River Tinto 24/07/18 42.809618, -8.632687 
11 River Tinto 06/09/18 42.809618, -8.632687 
12 River Barbadas 29/07/18 42.321127, -7.879475 
13 River Tinto 24/07/18 42.825999, -8.611045 
14 River Arnoia 29/07/18 42.201042, -7.969702 
15 Tap Cartelle 29/07/18 - 
16 River Tambre 06/09/18 42.946338, -8.528260 
17 Tap Santiago 06/09/18 - 
18 River Ulla 09/09/18 42.755205, -8.559375 
19 Tap Teo 09/09/18 - 
20 River Anllóns 31/09/18 43.211888, -8.680268 
21 Tap Carballo 31/09/18 - 







Table S3. Normalized values with their standard deviations (SD) of responses obtained 
for aliquots of the same treated wastewater sample, spiked before and after the 















EPR 84 4 
OLM 84 5 
VALA 83 4 
LOS 86 2 
CAN 83 2 
TEL 82 2 
IRB 87 6 




Table S4. Data corresponding to the consumption of sartan pharmaceuticals in Spain 
during year 2017. 
Compound 
aDHD 







(Kg x 103) 
EPR 0.845 600 8.633 
OLM 7.053 20 2.402 
LOS 10.061 50 8.566 
CAN 9.519 8 1.297 
TEL 5.553 40 3.782 
IRB 4.599 150 11.746 
VAL 13.701 80 18.663 
a Values obtained from the AEMPS without considering the combination of sartans with other drugs. 
b Daily dose recommended by the World Health Organization. 






Table S5. Proposed formula, rings and double bond equivalents (RDBs) and normalized scores 















ESI (+) IRB-OH C25H28N6O2 15 445.2347 445.2341 -1.3 90.4 
ESI (-) IRB-OH C25H28N6O2 15 443.2198 443.2201 0.7 98.3 





































Fig. S1. Overlay of UPLC-ESI-MS/MS chromatograms of VALA in a tap water sample 
(sample code 15, Table 4, measured concentration 64 ng L-1) and in a procedural 
blank. A, Q1 transition. B, Q2 transition. 
Time
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Fig. S2. ESI(-) Accurate product ion spectra obtained for E-EPR (A) and the isomer (identified as Z-EPR) obtained after sunlight photolysis of an 







Fig. S3. Extracted ion chromatograms corresponding to the [M+H]+ ions of IRB and 
IRB-OH (A); LOS and LOS-OH1 and LOS-OH2 (B) in the SPE extract from a non-






Fig. S4. ESI(+) accurate product ion spectra for IRB, LOS and the entities assigned to 
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